Sequana Medical N.V. — AGM Information 2021

May 27, 2021

EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING SEQUANA MEDICAL NV

SHARE CAPITAL, SHARES, ARTICLES OF ASSOCIATION

Today, TWENTY-SEVEN MAY TWO THOUSAND TWENTY-ONE

Before us, Mr. Dirk DELBAERE, notary public based in Ghent (5th canton), on behalf of the limited liability company (besloten vennootschap) 'Notaris Dirk Delbaere', with registered office at Belgium, 9050 Ghent (Ledeberg), Brusselsesteenweg 53, RPR Ghent, section Ghent 0554.886.718, VAT number BE0554.886.718; at "AA Tower", Technologiepark 122, 9052 Ghent, Belgium.

IS HELD

The extraordinary general meeting of the holders of securities issued by "SEQUANA MEDICAL", limited liability company (naamloze vennootschap) under Belgian law, with registered office at "AA Tower", Technologiepark 122, 9052 Ghent, Belgium, hereinafter referred to as the "Company".

[…] DECLARATIONS BY THE CHAIRPERSON

The Chairperson declares and instructs Us, notary public, to act as follows in a notarial deed:

I. The meeting of today has the following agenda:

1. Submission of the special report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the authorised capital

Consideration, discussion and submission of the special report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the powers granted to the Board of Directors under the authorised capital, as set out below in item 2 of the agenda of the extraordinary general shareholders' meeting, and setting out the specific circumstances in which the Board of Directors will be able to use its powers under the authorised capital, and the purposes that it should pursue.

2. Renewal of the authorisation to the Board of Directors to increase the share capital within the framework of the authorised capital

Proposed resolution: The extraordinary general shareholders' meeting resolves to renew the authorisation to the Board of Directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate amount equal to up to 100% of the amount of the share capital of the Company, and this in accordance with the terms and conditions set forth in the special report of the Board of Directors prepared in accordance with Article 7:199 of the Belgian Companies and Associations Code, as referred to in agenda item 1 of this extraordinary general shareholders' meeting. Consequently, the extraordinary general shareholders' meeting resolves to delete Article 8 "Authorised capital" of the Articles of Association of the Company entirely and to replace it with the following text (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders' meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of the Company's share capital at the time of the general shareholders' meeting approving the authorised capital):

"8. AUTHORISED CAPITAL

The board of directors is authorised to increase the share capital of the company on one or several occasions by a maximum aggregate amount of [100% of the company's share capital at the time of the adoption of the new authorised capital].

The board of directors may increase the share capital by contributions in cash or in kind, by capitalisation of reserves, whether available or unavailable for distribution, and capitalisation of issue premiums, with or without the issuance of new shares, with or without voting rights, that will have the rights as will be determined by the board of directors. The board of directors is also authorised to use this authorisation for the issuance of convertible bonds or subscription rights, bonds with subscription rights or other securities.

This authorisation is valid for a period of five years as from the date of publication in the Annexes to the Belgian Official Gazette of an extract of the minutes of the extraordinary general shareholders' meeting of the company held on [date of the general shareholders' meeting approving the renewed authorised capital].

In the event of a capital increase decided by the board of directors within the framework of the authorised capital, all issue premiums booked, if any, will be accounted for in accordance with the provisions of these articles of association.

The board of directors is authorised, when exercising its powers within the framework of the authorised capital, to restrict or cancel, in the interest of the company, the preferential subscription rights of the shareholders. This restriction or cancellation of the preferential subscription rights can also be done in favour of members of the personnel of the company or of its subsidiaries, or in favour of one or more persons other than members of the personnel of the company or of its subsidiaries.

The board of directors is authorised, with the right of substitution, to amend the articles of association, after each capital increase that has occurred within the framework of the authorised capital, in order to bring them in conformity with the new situation of the share capital and the shares."

3. Submission of reports in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code relating to the proposal to issue 1,000,000 new 2021 Share Options

Consideration, discussion and submission of:

(a) the report of the Board of Directors of the Company in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 1,000,000 new subscription rights for shares of the Company (the "2021 Share Options"), pursuant to a share option plan named "the 2021 Share Option Plan", and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of Article 1:27 of the Belgian Companies and Associations Code (the "Selected Participants"); and

(b) the report of the Statutory Auditor of the Company in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 1,000,000 2021 Share Options, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants.

4. Proposal to issue 2021 Share Options

Proposed resolution: The extraordinary general shareholders' meeting resolves to approve the issuance of 1,000,000 2021 Share Options, pursuant to a share option plan named the "2021 Share Option Plan", and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants. In view thereof, the general shareholders' meeting resolves as follows:

(a) Terms and conditions of the 2021 Share Options: The terms and conditions of the 2021 Share Options (including, but not limited to, the exercise price of the 2021 Share Options) shall be as set out in the annex to the report of the Board of Directors referred to in point 3(a) of the agenda (for the purpose of this resolution, the "Plan"), a copy of which shall remain attached to the minutes reflecting the present resolution. The 2021 Share Options have a term of ten years as from their issue date;

(b) Underlying shares: Each 2021 Share Option shall entitle the holder thereof to subscribe for one (1) new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2021 Share Options shall have the same rights and benefits as, and rank pari passu in all respects, including as to entitlements to dividends and distributions, with the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and distributions in respect of which the relevant record date or due date falls on or after the date of issue of the shares;

(c) Disapplication of the preferential subscription right to the benefit of the Selected Participants: The general shareholders' meeting resolves, in accordance with Article 7:191 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants (being the members of the personnel of the Company and its subsidiaries from time to time), and to approve the possibility for the Company to grant the 2021 Share Options to the Selected Participants, as further explained in the report of the Board of Directors referred to in point 3(a) of the agenda and the terms and conditions of the Plan;

(d) Confirmation of the subscription of 2021 Share Options by the Company: The general shareholders' meeting resolves to approve and confirm that the Company will be able to subscribe for the 2021 Share Options, with a view to creating a pool of outstanding 2021 Share Options available for further grants to Selected Participants. The Company may not, however, exercise the 2021 Share Options for its own account;

(e) Conditional capital increase and issue of new shares: The general shareholders' meeting resolves, subject to, and to the extent of the exercise of 2021 Share Options, to increase the Company's share capital and to issue the relevant number of new shares issuable upon the exercise of the 2021 Share Options. Subject to, and in accordance with the provisions of the Plan, upon exercise of the 2021 Share Options and issue of new shares, the aggregate amount of the exercise price of the 2021 Share Options will be allocated to the share capital of the Company. To the extent that the amount of the exercise price of the 2021 Share Options, per share to be issued upon exercise of the 2021 Share Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to be issued upon exercise of the 2021 Share Options, equal to such fractional value shall be booked as share capital, whereby the balance shall be booked as issue premium. Following the capital increase and issuance of new shares, each new and existing share shall represent the same fraction of the share capital of the Company;

(f) Issue premium: Any issue premium that will be booked in connection with the 2021 Share Options shall be accounted for on a non-distributable account on the liabilities side of the Company's balance sheet under its net equity, and the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution of the general shareholders' meeting passed in the manner required for an amendments to the Company's Articles of Association;

(g) Powers of attorney: The Board of Directors is authorised to implement and execute the resolutions passed by the general shareholders' meeting in connection with the 2021 Share Options, and to take all steps and carry out all formalities that shall be required by virtue of the Plan, the Company's Articles of Association and applicable law in order to issue or transfer the shares upon exercise of the 2021 Share Options. Furthermore, each Director of the Company, and each member of the executive management of the Company, each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the 2021 Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company's Articles of Association in order to reflect the new share capital and number of outstanding shares following the exercise of the 2021 Share Options, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the 2021 Share Options to trading on the regulated market of Euronext Brussels (or such other markets on which the Company's shares will be trading at that time);

(h) Waiver: The general shareholders' meeting acknowledges that the 2021 Share Options to be granted under the "2021 Share Option Plan" shall not be considered "variable remuneration", "fixed remuneration" or "annual remuneration" within the meaning of the Belgian Companies and Associations Code (including for, but not limited to, the purposes of Articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code) and the 2020 Corporate Governance Code (including for, but not limited to, the purposes of provision 7.11 of the 2020 Corporate Governance Code). In accordance with Article 7:91, 7:108 and 7:121 (as applicable) of the Belgian Companies and Associations Code, the general shareholders' meetings approves the vesting conditions and mechanisms of the 2021 Share Options, as included in the Plan; and

(i) Approval in accordance with Article 7:151 of the Belgian Companies and Associations Code: The general shareholders' meeting resolves to take note, approve and ratify, insofar as required in accordance with Article 7:151 of the Belgian Companies and Associations Code, all clauses included in the Plan, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the scope of Article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it), including, without limitation, the automatic accelerated vesting mechanism upon acquisition as defined in the Plan. The general shareholders' meeting grants a special power of attorney to each Director of the Company, notary public Dirk Delbaere, and to Fin-2K BV, represented by Kirsten Van Bockstaele (Chief Financial Officer), each acting alone and with power of substitution, for the purpose of carrying out the formalities required by Article 7:151 of the Belgian Companies and Associations Code with respect to this resolution.

[…]

IV. Verification of the attendance quorum

The attendance lists show that 11,253,799 shares are represented.

Consequently, 11,253,799 shares out of a total of 18,576,252 shares, each representing an equal part of the share capital, are represented.

In accordance with Article 7:153 of the Companies and Associations Code, a quorum of at least fifty per cent (50%) of the outstanding shares must be represented at this meeting for the deliberation and voting on the items referred to in the agenda of the present meeting.

It follows from the aforementioned that this quorum has been reached.

[…]

DECISIONS

The meeting starts with the agenda and adopts subsequently the following decisions:

1. Submission of the special report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the authorised capital

Submission of the special report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the powers granted to the Board of Directors under the authorised capital, as set out below in item 2 of the agenda of the extraordinary general shareholders' meeting, and setting out the specific circumstances in which the Board of Directors will be able to use its powers under the authorised capital, and the purposes that it should pursue.

This report is signed "ne varietur" by the members of the bureau and by me, notary public. It will be kept in the archives of the Company.

2. Renewal of the authorisation to the Board of Directors to increase the share capital within the framework of the authorised capital

Proposed resolution: The extraordinary general shareholders' meeting resolves to renew the authorisation to the Board of Directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate amount equal to up to 100% of the amount of the share capital of the Company, and this in accordance with the terms and conditions set forth in the special report of the Board of Directors prepared in accordance with Article 7:199 of the Belgian Companies and Associations Code, as referred to in agenda item 1 of this extraordinary general shareholders' meeting. Consequently, the extraordinary general shareholders' meeting resolves to delete Article 8 "Authorised capital" of the Articles of Association of the Company entirely and to replace it with the following text (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders' meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of the Company's share capital at the time of the general shareholders' meeting approving the authorised capital):

"8. AUTHORISED CAPITAL

The board of directors is authorised to increase the share capital of the company on one or several occasions by a maximum aggregate amount of one million nine hundred twenty-four thousand eight hundred forty-six euros and thirty-nine cents (EUR 1,924,846.39).

The board of directors may increase the share capital by contributions in cash or in kind, by capitalisation of reserves, whether available or unavailable for distribution, and capitalisation of issue premiums, with or without the issuance of new shares, with or without voting rights, that will have the rights as will be determined by the board of directors. The board of directors is also authorised to use this authorisation for the issuance of convertible bonds or subscription rights, bonds with subscription rights or other securities.

This authorisation is valid for a period of five years as from the date of publication in the Annexes to the Belgian Official Gazette of an extract of the minutes of the extraordinary general shareholders' meeting of the company held on 27 May 2021.

In the event of a capital increase decided by the board of directors within the framework of the authorised capital, all issue premiums booked, if any, will be accounted for in accordance with the provisions of these articles of association.

The board of directors is authorised, when exercising its powers within the framework of the authorised capital, to restrict or cancel, in the interest of the company, the preferential subscription rights of the shareholders. This restriction or cancellation of the preferential subscription rights can also be done in favour of members of the personnel of the company or of its subsidiaries, or in favour of one or more persons other than members of the personnel of the company or of its subsidiaries.

The board of directors is authorised, with the right of substitution, to amend the articles of association, after each capital increase that has occurred within the framework of the authorised capital, in order to bring them in conformity with the new situation of the share capital and the shares."

Voting:

The proposal was put to the vote. The proposal is passed as set out below on the basis of the vote by letter forms and the voting instructions in the written proxies:

1/ Number of shares for which valid votes have been cast: 11,253,799.

2/ Percentage of the abovementioned number of shares in the share capital: 60.58%.

3/ Number of shares validly casted: 11,253,799.

of which:

FOR	11,253,799
AGAINST	0
ABSTENTION	0

The proposal has therefore been adopted.

3. Submission of reports in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code relating to the proposal to issue 1,000,000 new 2021 Share Options

Submission of:

(a) the report of the Board of Directors of the Company in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 1,000,000 new subscription rights for shares of the Company (the "2021 Share Options"), pursuant to a share option plan named "the 2021 Share Option Plan", and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of Article 1:27 of the Belgian Companies and Associations Code (the "Selected Participants"); and

(b) the report of the Statutory Auditor of the Company in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 1,000,000 2021 Share Options, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants.

Both reports are signed "ne varietur" by the members of the bureau and by me, notary public, and will be filed and made public in accordance with article 2:8 and 2:14,4° of the Belgian Companies and Associations Code.

4. Proposal to issue 2021 Share Options

Proposed resolution: The extraordinary general shareholders' meeting resolves to approve the issuance of 1,000,000 2021 Share Options, pursuant to a share option plan named the "2021 Share Option Plan", and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants. In view thereof, the general shareholders' meeting resolves as follows:

(a) Terms and conditions of the 2021 Share Options: The terms and conditions of the 2021 Share Options (including, but not limited to, the exercise price of the 2021 Share Options) shall be as set out in the annex to the report of the Board of Directors referred to in point 3(a) of the agenda (for the purpose of this resolution, the "Plan"), a copy of which shall remain attached to the minutes reflecting the present resolution. The 2021 Share Options have a term of ten years as from their issue date;

(b) Underlying shares: Each 2021 Share Option shall entitle the holder thereof to subscribe for one (1) new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2021 Share Options shall have the same rights and benefits as, and rank pari passu in all respects, including as to entitlements to dividends and distributions, with the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and distributions in respect of which the relevant record date or due date falls on or after the date of issue of the shares;

(c) Disapplication of the preferential subscription right to the benefit of the Selected Participants: The general shareholders' meeting resolves, in accordance with Article 7:191 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants (being the members of the personnel of the Company and its subsidiaries from time to time), and to approve the possibility for the Company to grant the 2021 Share Options to the Selected Participants, as further explained in the report of the Board of Directors referred to in point 3(a) of the agenda and the terms and conditions of the Plan;

(d) Confirmation of the subscription of 2021 Share Options by the Company: The general shareholders' meeting resolves to approve and confirm that the Company will be able to subscribe for the 2021 Share Options, with a view to creating a pool of outstanding 2021 Share Options available for further grants to Selected Participants. The Company may not, however, exercise the 2021 Share Options for its own account;

(e) Conditional capital increase and issue of new shares: The general shareholders' meeting resolves, subject to, and to the extent of the exercise of 2021 Share Options, to increase the Company's share capital and to issue the relevant number of new shares issuable upon the exercise of the 2021 Share Options. Subject to, and in accordance with the provisions of the Plan, upon exercise of the 2021 Share Options and issue of new shares, the aggregate amount of the exercise price of the 2021 Share Options will be allocated to the share capital of the Company. To the extent that the amount of the exercise price of the 2021 Share Options, per share to be issued upon exercise of the 2021 Share Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to be issued upon exercise of the 2021 Share Options, equal to such fractional value shall be booked as share capital, whereby the balance shall be booked as issue premium. Following the capital increase and issuance of new shares, each new and existing share shall represent the same fraction of the share capital of the Company;

(f) Issue premium: Any issue premium that will be booked in connection with the 2021 Share Options shall be accounted for on a non-distributable account on the liabilities side of the Company's balance sheet under its net equity, and the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution of the general shareholders' meeting passed in the manner required for an amendments to the Company's Articles of Association;

(g) Powers of attorney: The Board of Directors is authorised to implement and execute the resolutions passed by the general shareholders' meeting in connection with the 2021 Share Options, and to take all steps and carry out all formalities that shall be required by virtue of the Plan, the Company's Articles of Association and applicable law in order to issue or transfer the shares upon exercise of the 2021 Share Options. Furthermore, each Director of the Company, and each member of the executive management of the Company, each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the 2021 Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company's Articles of Association in order to reflect the new share capital and number of outstanding shares following the exercise of the 2021 Share Options, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the 2021 Share Options to trading on the regulated market of Euronext Brussels (or such other markets on which the Company's shares will be trading at that time);

(h) Waiver: The general shareholders' meeting acknowledges that the 2021 Share Options to be granted under the "2021 Share Option Plan" shall not be considered "variable remuneration", "fixed remuneration" or "annual remuneration" within the meaning of the Belgian Companies and Associations Code (including for, but not limited to, the purposes of Articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code) and the 2020 Corporate Governance Code (including for, but not limited to, the purposes of provision 7.11 of the 2020 Corporate Governance Code). In accordance with Article 7:91, 7:108 and 7:121 (as applicable) of the Belgian Companies and Associations Code, the general shareholders' meetings approves the vesting conditions and mechanisms of the 2021 Share Options, as included in the Plan; and

(i) Approval in accordance with Article 7:151 of the Belgian Companies and Associations Code: The general shareholders' meeting resolves to take note, approve and ratify, insofar as required in accordance with Article 7:151 of the Belgian Companies and Associations Code, all clauses included in the Plan, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the scope of Article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it), including, without limitation, the automatic accelerated vesting mechanism upon acquisition as defined in the Plan. The general shareholders' meeting grants a special power of attorney to each Director of the Company, notary public Dirk Delbaere, and to Fin-2K BV, represented by Kirsten Van Bockstaele (Chief Financial Officer), each acting alone and with power of substitution, for the purpose of carrying out the formalities required by Article 7:151 of the Belgian Companies and Associations Code with respect to this resolution.

Voting:

The proposal was put to the vote. The proposal is passed as set out below on the basis of the vote by letter forms and the voting instructions in the written proxies:

1/ Number of shares for which valid votes have been cast: 11,253,799.

2/ Percentage of the abovementioned number of shares in the share capital: 60.58%.

3/ Number of shares validly casted: 11,253,799.

of which:

FOR	11,253,799
AGAINST	0
ABSTENTION	0

The proposal has therefore been adopted.

Coordination of the Articles of Association

The meeting instructs notary public Delbaere to draw up the coordinated text of the Articles of Association of the Company, sign them and deposit them with the registry of the competent Enterprise Court in accordance with the relevant legal provisions.

[…]

CLOSING OF THE MEETING

There being no further business, the meeting is adjourned. […]